[go: up one dir, main page]

ATE383877T1 - Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren - Google Patents

Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren

Info

Publication number
ATE383877T1
ATE383877T1 AT00938100T AT00938100T ATE383877T1 AT E383877 T1 ATE383877 T1 AT E383877T1 AT 00938100 T AT00938100 T AT 00938100T AT 00938100 T AT00938100 T AT 00938100T AT E383877 T1 ATE383877 T1 AT E383877T1
Authority
AT
Austria
Prior art keywords
hypoxia
substances
identification
transcriptional responses
modify
Prior art date
Application number
AT00938100T
Other languages
English (en)
Inventor
David Livingston
Andrew Kung
Shoumo Bhattacharya
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE383877T1 publication Critical patent/ATE383877T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00938100T 1999-06-04 2000-06-02 Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren ATE383877T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13762599P 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
ATE383877T1 true ATE383877T1 (de) 2008-02-15

Family

ID=22478315

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00938100T ATE383877T1 (de) 1999-06-04 2000-06-02 Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren

Country Status (8)

Country Link
EP (1) EP1198255B1 (de)
JP (1) JP4902915B2 (de)
AT (1) ATE383877T1 (de)
CA (1) CA2376438A1 (de)
DE (1) DE60037813T2 (de)
ES (1) ES2299427T3 (de)
PT (1) PT1198255E (de)
WO (1) WO2000074725A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
US7919274B2 (en) * 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
AT500023B1 (de) * 2001-09-27 2007-09-15 Bmt Medizinische Forschung Und Funktioneller screen für transskriptionsfaktoren
US7358043B2 (en) * 2001-10-16 2008-04-15 Duke University Proteomic interaction and genomic action determinations in the presence of associated redox state conditions
WO2003045440A1 (en) * 2001-11-28 2003-06-05 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein
AU2003201798A1 (en) * 2002-01-11 2003-09-02 Angio Genetics Sweden Ab Hif-1 alpha proteins mutated in the c-terminal transactivation domain
GB0206711D0 (en) * 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
GB0211920D0 (en) 2002-05-23 2002-07-03 Isis Innovations Ltd Assay
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN1816327B (zh) * 2003-06-06 2010-09-08 菲布罗根公司 增强红细胞生成的HIFα稳定剂的应用
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005034929A2 (en) * 2003-10-10 2005-04-21 Fibrogen, Inc. Tissue remodeling and vascularization
JP4682359B2 (ja) * 2004-12-28 2011-05-11 独立行政法人産業技術総合研究所 神経細胞分化誘導剤
CN100418574C (zh) * 2005-10-26 2008-09-17 王成球 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
KR100711939B1 (ko) 2005-12-29 2007-05-02 한국화학연구원 형질전환 세포주 및 재조합 바이러스를 이용한 스크리닝방법
DK3026044T3 (en) 2006-06-26 2019-02-18 Akebia Therapeutics Inc PROLYL HYDROXYLASE INHIBITORS AND METHODS FOR USE
KR100860060B1 (ko) 2006-10-12 2008-09-24 한국과학기술연구원 HIF-1α C-말단 펩타이드와 CBP 또는 p300단백질과의 결합을 정량분석하는 방법 및 상기 방법을이용한 단백질 복합체 형성을 저해하는 억제제의 스크리닝방법
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658784A (en) * 1994-04-14 1997-08-19 Dana-Farber Cancer Institute, Inc. Nucleic acid encoding transcription factor p300 and uses of p300
CA2236489A1 (en) * 1997-07-14 1999-01-14 Human Genome Sciences Novel compounds
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants

Also Published As

Publication number Publication date
JP2003501061A (ja) 2003-01-14
DE60037813D1 (de) 2008-03-06
EP1198255A1 (de) 2002-04-24
JP4902915B2 (ja) 2012-03-21
DE60037813T2 (de) 2009-01-15
ES2299427T3 (es) 2008-06-01
EP1198255A4 (de) 2005-06-15
EP1198255B1 (de) 2008-01-16
CA2376438A1 (en) 2000-12-14
PT1198255E (pt) 2008-04-21
WO2000074725A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
ATE383877T1 (de) Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren
EP1231914A4 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE280160T1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
DE69635821D1 (de) Vorrichtung zum Bestimmen von Akne, Komedonen und Bakterien auf der menschlichen Haut
ATE483976T1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
FI971412L (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
PT1153024E (pt) 2-amino-6-anilino-purinas e sua utilizacao como medicamentos
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
DE69929257D1 (de) Vorrichtung zum Bedrucken und Anbringen von Klebeband an einen Gegenstand.
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
TR200100054T2 (tr) Paroksetin metansülfonat
DE69905170T2 (de) Thiazolopyrimidinderivate
ATE404667T1 (de) Chromatin-regulatorgene
DK1313462T3 (da) Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer
DE60012138D1 (de) Gerät zur behandlung von fibrillation
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
DE3850433D1 (de) Allergiebehandlung und Zusammensetzung dafür.
SE8305160D0 (sv) Antibakteriella emnen
DE60328931D1 (de) Wässrige Zubereitungen von Perfluoropolyetherphosphaten und ihre Verwendung für die ölabweisende Behandlung von Papier
PT922703E (pt) Benzocicloalcenos substituidos e sua utilizacao como substancias com efeito analgesico
ATE328000T1 (de) Phospholipidester von clofarabin
DE69930844D1 (de) Inhibitoren von mycobakterien
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
DE69800080D1 (de) Antikörper gegen das Prorenin Profragment, reninaktive Substanz die diese enthält und Prorenintest die diese verwendet
DE69911237D1 (de) Selektion und verwendung von milchsäurebakterienstämmen, die die nicht-spezifische immunität modulieren können

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1198255

Country of ref document: EP

REN Ceased due to non-payment of the annual fee